GYRE
HealthcareGyre Therapeutics, Inc. · Biotechnology · $590M
What is Gyre Therapeutics, Inc.?
Gyre Therapeutics is a small-cap pharmaceutical company focused on developing and commercializing drugs that target organ fibrosis — a serious condition involving the hardening or scarring of organ tissue. Headquartered in San Diego, California, it operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics develops small-molecule drugs with anti-inflammatory and anti-fibrotic properties. Its lead approved product, ETUARY (Pirfenidone), treats idiopathic pulmonary fibrosis and is being studied for additional fibrotic diseases. The company also advances F351 (Hydronidone), a derivative of Pirfenidone, through late-stage trials for liver fibrosis. Earlier-stage candidates target acute liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension.
Gyre Therapeutics was founded in 2006 and is based in San Diego, California.
- ETUARY (Pirfenidone) — approved anti-fibrotic for idiopathic pulmonary fibrosis
- F351 (Hydronidone) — Phase 3 candidate for chronic hepatitis B liver fibrosis
- F573 — Phase 2 candidate for acute and acute-on-chronic liver failure
- Preclinical pipeline targeting COPD and pulmonary arterial hypertension
Is GYRE a Good Stock to Buy?
UQS Score rates GYRE as Below Average overall.
The Risk pillar stands out as the clearest bright spot in GYRE's profile, suggesting the company carries relatively manageable downside characteristics compared to many small-cap biotech peers. This is notable given the inherently uncertain nature of clinical-stage drug development.
Quality, Moat, and Growth all register as Weak, reflecting the early-stage nature of most of the pipeline and limited competitive differentiation. The Valuation pillar reads as Elevated, meaning the current price may not offer a margin of safety relative to fundamentals.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does GYRE pay dividends?
No — Gyre Therapeutics, Inc. does not currently pay a dividend.
Gyre Therapeutics does not currently pay a dividend. This is typical for clinical-stage pharmaceutical companies, which generally reinvest available capital into research, clinical trials, and regulatory activities rather than returning cash to shareholders.
When does GYRE report earnings?
Gyre Therapeutics reports earnings on a quarterly cadence, consistent with US-listed equities.
As a small-cap pharmaceutical company with a developing pipeline, quarterly results are often shaped more by clinical milestones and operating expenses than by commercial revenue trends. Investors typically monitor pipeline progress alongside financial updates.
For the most recent quarter's results, visit Gyre Therapeutics' investor relations page directly.
GYRE Price History
-86.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Gyre Therapeutics, Inc.?
Based on Gyre Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
GYRE Long-term Outlook
GYRE's Growth pillar registers as Weak, reflecting the limited near-term revenue visibility common to companies reliant on pipeline advancement. The Risk pillar, however, reads as Strong, which may indicate the balance sheet or operational structure provides some buffer. The Elevated Valuation reading suggests the market may already be pricing in optimistic pipeline outcomes, leaving limited room for disappointment.
Growth drivers
- Potential label expansions for ETUARY into additional fibrotic indications
- Phase 3 readouts for F351 in chronic hepatitis B liver fibrosis
- Broader anti-fibrotic pipeline progressing through early and mid-stage trials
Key risks
- Clinical trial failures or delays across multiple pipeline candidates
- Elevated valuation relative to current commercial-stage fundamentals
- Competitive pressure from larger, better-resourced pharmaceutical companies in fibrosis
GYRE vs Peers
Gyre Therapeutics operates in a competitive small-cap biotech space alongside several peers focused on specialty therapeutic development.
SELLAS focuses on cancer immunotherapy rather than fibrosis, representing a distinct therapeutic approach within the broader rare-disease biotech landscape.
Jade Biosciences is an early-stage company pursuing novel biologics, differentiating itself from GYRE's small-molecule anti-fibrotic strategy.
BridgeBio Oncology centers on precision oncology, targeting a different disease area than GYRE's fibrosis and inflammatory disease focus.
Frequently Asked Questions
What does Gyre Therapeutics do?
Gyre Therapeutics develops and commercializes small-molecule drugs designed to combat organ fibrosis — the scarring or hardening of organ tissue. Its pipeline spans approved treatments for pulmonary fibrosis, late-stage candidates for liver fibrosis, and earlier-stage programs targeting additional inflammatory and fibrotic conditions.
Does GYRE pay dividends?
No, Gyre Therapeutics does not pay a dividend. The company is in an active pipeline-development phase, and available capital is directed toward clinical trials and research rather than shareholder distributions. Income-focused investors should factor this into their assessment.
When does GYRE report earnings?
Gyre Therapeutics follows a standard quarterly reporting cadence for US-listed companies. For exact dates and the most recent financial results, check the investor relations section of the company's official website.
Is GYRE a good stock to buy?
UQS Score rates GYRE as Below Average. The Risk pillar is the strongest element of the profile, but Quality, Moat, and Growth all read as Weak, and Valuation is Elevated. Investors should weigh these factors carefully. The full pillar breakdown is available to UQS Pro members.
Is GYRE overvalued?
GYRE's Valuation pillar is rated Elevated within the UQS framework, suggesting the current market price may already reflect optimistic expectations for pipeline success. This is a common dynamic for clinical-stage biotechs where commercial revenue remains limited.
How does GYRE compare to its competitors?
GYRE competes in the small-cap biotech space alongside companies like SELLAS Life Sciences, Jade Biosciences, and BridgeBio Oncology Therapeutics. Unlike peers focused on oncology or immunotherapy, GYRE's differentiation lies in its dedicated anti-fibrotic and anti-inflammatory drug platform. Full comparative UQS scores are available on each company's page.
What is GYRE's market cap bracket?
Gyre Therapeutics is classified as a small-cap company. Small-cap biotechs typically carry higher risk and volatility than large- or mega-cap peers, but may also offer greater upside if clinical programs succeed.
Who founded Gyre Therapeutics?
Gyre Therapeutics was founded in 2006. Detailed founding history and leadership information is publicly available through the company's official disclosures and investor relations materials.
Is GYRE a long-term quality investment?
From a long-term quality perspective, GYRE's UQS profile shows meaningful weaknesses across Quality, Moat, and Growth pillars. While the Risk pillar is relatively strong, sustained long-term quality typically requires durable competitive advantages and consistent financial performance — areas where GYRE's current profile is limited.
What is the main competitive advantage of Gyre Therapeutics?
Gyre Therapeutics' primary differentiation is its focused anti-fibrotic platform, anchored by an approved product in ETUARY and a pipeline of structurally related compounds. However, the UQS Moat pillar rates as Weak, indicating this advantage may not yet be deeply entrenched relative to the broader pharmaceutical sector.
Unlock Full GYRE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare GYRE side-by-side with competitors using standardized UQS data
- ✓Track score changes over time as pipeline milestones and financials evolve
- ✓Screen for higher-rated healthcare stocks using UQS preset filters
Pro Analysis
GYRE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 29.8 | 18.0 | 32.0 | 24.9 | 82.4 | 0.0 | -4.7 |
| Apr 18, 2026 | 34.5 | 32.9 | 32.0 | 26.8 | 82.4 | 4.1 | -0.5 |
| Apr 15, 2026 | 35.0 | 32.9 | 32.0 | 26.8 | 82.4 | 7.0 | 0.0 |
| Apr 14, 2026 | 35.0 | 32.9 | 32.0 | 26.8 | 82.4 | 7.2 | -0.1 |
| Apr 10, 2026 | 35.1 | 32.9 | 32.0 | 26.8 | 82.4 | 7.6 | 0.0 |
| Apr 3, 2026 | 35.1 | 32.9 | 32.0 | 26.8 | 82.4 | 7.7 | 0.0 |
| Apr 2, 2026 | 35.1 | 32.9 | 32.0 | 26.8 | 82.4 | 7.6 | — |
GYRE — Pillar Breakdown
Quality
— 18.0/100 (25%)Gyre Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 24.9/100 (20%)Gyre Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 82.4/100 (15%)Gyre Therapeutics, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Gyre Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Enterprise value multiple relative to sector median.
Moat
— 32/100 (25%)Gyre Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GYRE.
Score Composition
Financial Data
More Stock Analysis
How is the GYRE UQS Score Calculated?
The UQS (Unified Quality Score) for Gyre Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Gyre Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Gyre Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.